BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,704,790 | -9.9% | 363,137 | +8.8% | 0.06% | -7.7% |
| Q2 2023 | $15,212,530 | +36.4% | 333,901 | +21.4% | 0.06% | +18.2% |
| Q1 2023 | $11,151,364 | +406.2% | 274,935 | +536.1% | 0.06% | +323.1% |
| Q4 2022 | $2,203,076 | -63.9% | 43,223 | -61.8% | 0.01% | -66.7% |
| Q3 2022 | $6,100,000 | +100.6% | 113,250 | +188.8% | 0.04% | +143.8% |
| Q1 2022 | $3,041,000 | -97.4% | 39,216 | -97.1% | 0.02% | -97.4% |
| Q4 2021 | $116,462,000 | +41.3% | 1,356,733 | +32.4% | 0.61% | +35.3% |
| Q3 2021 | $82,447,000 | +1902.1% | 1,025,082 | +1903.9% | 0.45% | +1847.8% |
| Q2 2021 | $4,118,000 | -42.0% | 51,155 | -39.2% | 0.02% | -48.9% |
| Q1 2021 | $7,100,000 | +41.2% | 84,181 | +34.4% | 0.04% | +40.6% |
| Q4 2020 | $5,027,000 | +200.1% | 62,647 | +200.7% | 0.03% | +146.2% |
| Q3 2020 | $1,675,000 | -94.0% | 20,831 | -94.0% | 0.01% | -95.7% |
| Q1 2020 | $28,118,000 | -77.1% | 346,323 | -76.4% | 0.30% | -72.6% |
| Q4 2019 | $122,840,000 | +8002.9% | 1,469,025 | +7837.2% | 1.10% | +5694.7% |
| Q2 2019 | $1,516,000 | +17.2% | 18,508 | -5.9% | 0.02% | -9.5% |
| Q4 2018 | $1,294,000 | – | 19,660 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |